Diarylureas As Allosteric Modulators of the Cannabinoid CB1 Receptor: Structure-activity Relationship Studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1)

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2014 Aug 28

PMID 25162172

Citations 27

Authors

Nadezhda German

Ann M Decker

Brian P Gilmour

Elaine A Gay

Jenny L Wiley

Brian F Thomas

Yanan Zhang

Affiliations

Soon will be listed here.

Abstract

The recent discovery of allosteric modulators of the CB1 receptor including PSNCBAM-1 (4) has generated significant interest in CB1 receptor allosteric modulation. Here in the first SAR study on 4, we have designed and synthesized a series of analogs focusing on modifications at two positions. Pharmacological evaluation in calcium mobilization and binding assays revealed the importance of alkyl substitution at the 2-aminopyridine moiety and electron deficient aromatic groups at the 4-chlorophenyl position for activity at the CB1 receptor, resulting in several analogs with comparable potency to 4. These compounds increased the specific binding of [(3)H]CP55,940, in agreement with previous reports. Importantly, 4 and two analogs dose-dependently reduced the Emax of the agonist curve in the CB1 calcium mobilization assays, confirming their negative allosteric modulator characteristics. Given the side effects associated with CB1 receptor orthosteric antagonists, negative allosteric modulators provide an alternative approach to modulate the pharmacologically important CB1 receptor.

Citing Articles

Discovery and Characterization of the First Nonpeptide Antagonists for the Relaxin-3/RXFP3 System.

Gay E, Guan D, Van Voorhies K, Vasukuttan V, Mathews K, Besheer J J Med Chem. 2022; 65(11):7959-7974.

PMID: 35594150 PMC: 9255433. DOI: 10.1021/acs.jmedchem.2c00508.

Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior.

Nguyen T, Gamage T, Finlay D, Decker A, Langston T, Barrus D J Med Chem. 2021; 65(1):257-270.

PMID: 34929081 PMC: 8969894. DOI: 10.1021/acs.jmedchem.1c01432.

Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids.

Nguyen T, Gamage T, Decker A, Finlay D, Langston T, Barrus D Bioorg Med Chem. 2021; 41:116215.

PMID: 34015703 PMC: 8506265. DOI: 10.1016/j.bmc.2021.116215.

Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development.

Hou L, Rong J, Haider A, Ogasawara D, Varlow C, Schafroth M J Med Chem. 2020; 64(1):123-149.

PMID: 33379862 PMC: 7877880. DOI: 10.1021/acs.jmedchem.0c01459.

Structural Optimization of the Diarylurea PSNCBAM-1, an Allosteric Modulator of Cannabinoid Receptor 1.

Dopart R, Immadi S, Lu D, Kendall D Curr Ther Res Clin Exp. 2020; 92:100574.

PMID: 32021660 PMC: 6994307. DOI: 10.1016/j.curtheres.2019.100574.

References

Perrey D, German N, Gilmour B, Li J, Harris D, Thomas B . Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor. J Med Chem. 2013; 56(17):6901-16. PMC: 3849818. DOI: 10.1021/jm400720h. View

Sammakia T, Hurley T . Studies on the Mechanism of Action of 2-Formyl-4-pyrrolidinopyridine: Isolation and Characterization of a Reactive Intermediate. J Org Chem. 2001; 64(13):4652-4664. DOI: 10.1021/jo982281n. View

Fay J, Farrens D . A key agonist-induced conformational change in the cannabinoid receptor CB1 is blocked by the allosteric ligand Org 27569. J Biol Chem. 2012; 287(40):33873-82. PMC: 3460482. DOI: 10.1074/jbc.M112.352328. View

Fulp A, Bortoff K, Seltzman H, Zhang Y, Mathews J, Snyder R . Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity. J Med Chem. 2012; 55(6):2820-34. PMC: 3319116. DOI: 10.1021/jm201731z. View

Mackie K . Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006; 46:101-22. DOI: 10.1146/annurev.pharmtox.46.120604.141254. View

Pamplona F, Ferreira J, Menezes de Lima Jr O, Duarte F, Bento A, Forner S . Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor. Proc Natl Acad Sci U S A. 2012; 109(51):21134-9. PMC: 3529012. DOI: 10.1073/pnas.1202906109. View

Zhang Y, Gilliam A, Maitra R, Damaj M, Tajuba J, Seltzman H . Synthesis and biological evaluation of bivalent ligands for the cannabinoid 1 receptor. J Med Chem. 2010; 53(19):7048-60. PMC: 3076737. DOI: 10.1021/jm1006676. View

Navarro H, Howard J, Pollard G, Carroll F . Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol. 2009; 156(7):1178-84. PMC: 2697692. DOI: 10.1111/j.1476-5381.2009.00124.x. View

Christopoulos A . Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov. 2002; 1(3):198-210. DOI: 10.1038/nrd746. View

10.

Pertwee R . Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006; 147 Suppl 1:S163-71. PMC: 1760722. DOI: 10.1038/sj.bjp.0706406. View

11.

Christopoulos A, Kenakin T . G protein-coupled receptor allosterism and complexing. Pharmacol Rev. 2002; 54(2):323-74. DOI: 10.1124/pr.54.2.323. View

12.

Jagerovic N, Fernandez-Fernandez C, Goya P . CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr Top Med Chem. 2008; 8(3):205-30. DOI: 10.2174/156802608783498050. View

13.

Price M, Baillie G, Thomas A, Stevenson L, Easson M, Goodwin R . Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005; 68(5):1484-95. DOI: 10.1124/mol.105.016162. View

14.

Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B . Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem. 2012; 287(44):36944-67. PMC: 3481297. DOI: 10.1074/jbc.M112.382481. View

15.

Jagerovic N, Hernandez-Folgado L, Alkorta I, Goya P, Martin M, Dannert M . Structural-activity relationship study on C-4 carbon atom of the CB1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides. Eur J Med Chem. 2005; 41(1):114-20. DOI: 10.1016/j.ejmech.2005.06.012. View

16.

Wang X, Horswill J, Whalley B, Stephens G . Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum. Mol Pharmacol. 2010; 79(4):758-67. DOI: 10.1124/mol.110.068197. View

17.

Ross R . Tuning the endocannabinoid system: allosteric modulators of the CB1 receptor. Br J Pharmacol. 2007; 152(5):565-6. PMC: 2190008. DOI: 10.1038/sj.bjp.0707349. View

18.

Handy S, Zhang Y, Bregman H . A modular synthesis of the lamellarins: total synthesis of lamellarin G trimethyl ether. J Org Chem. 2004; 69(7):2362-6. DOI: 10.1021/jo0352833. View

19.

Pertwee R . Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 2012; 367(1607):3353-63. PMC: 3481523. DOI: 10.1098/rstb.2011.0381. View

20.

Pacher P, Batkai S, Kunos G . The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58(3):389-462. PMC: 2241751. DOI: 10.1124/pr.58.3.2. View